person · Reporting owner

LOVE TED W

Disclosed activity across 10 companies

Tapewire entity: 893
SEC CIK: 0001188919

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMICUS THERAPEUTICS, INC.FOLD · Entity 51196	Director	June 04, 2020	June 08, 2020
GILEAD SCIENCES, INC.GILD · Entity 405	Director	April 30, 2026	May 04, 2026
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	August 31, 2026	September 02, 2026
LISATA THERAPEUTICS, INC.LSTA · Entity 7814	Director	September 17, 2026	September 29, 2026
Royalty Pharma plcRPRX · Entity 3100	Director	June 05, 2026	June 08, 2026
Structure Therapeutics Inc.GPCR · Entity 1222	Director	June 17, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMICUS THERAPEUTICS, INC.

Report date June 04, 2020 · Filed June 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	131,000	Reported balance After 2020-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-06-04 · Grant · Acquired 5,855 · Balance 131,000 F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	18,574	Reported balance After 2020-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-06-04 · Grant · Acquired 18,574 · Balance 18,574 F2: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.

F2: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant.

GILEAD SCIENCES, INC.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,484	Reported balance After 2026-04-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-04-30 · Grant · Acquired 1,146 · Balance 5,484 F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.84 · Expires 2036-04-30	Direct	4,884	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 4,884 · Balance 4,884 F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Jazz Pharmaceuticals plc

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	2,389	Ending reported balance After 2026-08-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-31 · Tax withholding · Disposed 6 · Balance 3,126 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 737 · Balance 2,389 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

LISATA THERAPEUTICS, INC.

Report date September 17, 2026 · Filed September 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,260	Reported balance Holding disclosure · report date 2026-09-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 19,260 F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's F2: (continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.
Series C Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's F2: (continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's

F2: (continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

F3: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.

Royalty Pharma plc

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	58,393	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 58,393 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Structure Therapeutics Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16	Direct	39,453	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cascadian Therapeutics, Inc.

Report date March 09, 2018 · Filed March 13, 2018

Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-03-09 transaction · row 1 1 source row Row 1 · 2018-03-09 · Other · Disposed 37,394 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-09 · Disposition to issuer · Disposed 13,927 · Balance 0 F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.

F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.

F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.

F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 576,318 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust 1	Reported balance After 2022-10-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 119,650 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust 2	Reported balance After 2022-10-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 119,650 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust 3	Reported balance After 2022-10-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 102,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Daughter	Reported balance After 2022-10-05 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 2,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Daughter	Reported balance After 2022-10-05 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 2,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 11,250 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-05 · Disposition to issuer · Disposed 26,865 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-05 · Disposition to issuer · Disposed 47,223 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-05 · Disposition to issuer · Disposed 63,768 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-10-05 · Disposition to issuer · Disposed 109,116 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-10-05 · Disposition to issuer · Disposed 141,400 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40	Direct	Reported balance After 2022-10-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-10-05 · Disposition to issuer · Disposed 114,515 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.60	Direct	Reported balance After 2022-10-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-10-05 · Disposition to issuer · Disposed 122,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.44	Direct	Reported balance After 2022-10-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-10-05 · Disposition to issuer · Disposed 145,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.82	Direct	Reported balance After 2022-10-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-10-05 · Disposition to issuer · Disposed 114,190 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.48	Direct	Reported balance After 2022-10-05 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2022-10-05 · Disposition to issuer · Disposed 132,433 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87	Direct	Reported balance After 2022-10-05 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2022-10-05 · Disposition to issuer · Disposed 118,090 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 1 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 15,575 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11	Direct	Reported balance After 2020-07-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F2: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 14,812 · Balance 0 F3: In connection with the Merger, these options were accelerated and canceled without payment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.

F2: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F3: In connection with the Merger, these options were accelerated and canceled without payment.

Seagen Inc.

Report date December 14, 2023 · Filed December 15, 2023

Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-12-14 transaction · row 1 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Disposed 4,255 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17	Direct	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Disposition to issuer · Disposed 4,460 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14	Direct	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13	Direct	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-14 · Disposition to issuer · Disposed 449 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.

F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2026 Filed Sep 2, 2026 21:28 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	737	$241.39	$177,904.36	Disclosure SEC source: 0001188919-26-000015 · edgardoc.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,389 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 31, 2026 Filed Sep 2, 2026 21:28 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	6	$244.06	$1,464.38	Disclosure SEC source: 0001188919-26-000015 · edgardoc.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,126 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 05, 2026 Filed Aug 7, 2026 21:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,605	$0.00	$0.00	Disclosure SEC source: 0001188919-26-000012 · edgardoc.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,132 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. Read SEC document
June 17, 2026 Filed Jun 18, 2026 21:00 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	GrantShare Option (right to buy) · Derivative	39,453	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0001188919-26-000010 · form4-06182026_050611.xml · derivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 Underlying: Ordinary Shares · 39,453 shares Expires 2036-06-16 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:27 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	4,545	$0.00	$0.00	Disclosure SEC source: 0001188919-26-000008 · wk-form4_1780950421.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,393 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
April 30, 2026 Filed May 4, 2026 20:28 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	4,884	$0.00 Strike: $130.84	$0.00	Disclosure SEC source: 0001188919-26-000004 · wk-form4_1777926511.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,884 Underlying: Common Stock · 4,884 shares Expires 2036-04-30 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. Read SEC document
April 30, 2026 Filed May 4, 2026 20:28 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	1,146	$0.00	$0.00	Disclosure SEC source: 0001188919-26-000004 · wk-form4_1777926511.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,484 F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. Read SEC document
February 26, 2026 Filed Mar 2, 2026 22:09 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,527	$0.00	$0.00	Disclosure SEC source: 0001188919-26-000002 · edgardoc.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,527 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document
June 23, 2025 Filed Jun 25, 2025 21:45 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	GrantShare Option (right to buy) · Derivative	51,804	$0.00 Strike: $7.37	$0.00	Disclosure SEC source: 0001415889-25-018217 · form4-06252025_050609.xml · derivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,804 Underlying: Ordinary Shares · 51,804 shares Expires 2035-06-22 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document
May 13, 2025 Filed May 14, 2025 21:11 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	7,614	$0.00	$0.00	Disclosure SEC source: 0001802768-25-000055 · wk-form4_1747257065.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,848 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
May 07, 2025 Filed May 8, 2025 22:22 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	6,809	$0.00 Strike: $98.90	$0.00	Disclosure SEC source: 0001127602-25-013747 · form4.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,809 Underlying: Common Stock · 6,809 shares Expires 2035-05-07 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025. Read SEC document
May 07, 2025 Filed May 8, 2025 22:22 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	1,516	$0.00	$0.00	Disclosure SEC source: 0001127602-25-013747 · form4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,338 F1 · security: Represents 1,516 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 7, 2025. Read SEC document
June 25, 2024 Filed Jun 27, 2024 20:15 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	GrantShare Option (right to buy) · Derivative	33,595	$0.00 Strike: $13.32	$0.00	Disclosure SEC source: 0001415889-24-018328 · form4-06272024_040609.xml · derivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,595 Underlying: Ordinary Shares · 33,595 shares Expires 2034-06-24 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 25, 2024. F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document
June 07, 2024 Filed Jun 10, 2024 20:16 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	9,293	$0.00	$0.00	Disclosure SEC source: 0001802768-24-000035 · wk-form4_1718050587.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,234 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
May 08, 2024 Filed May 9, 2024 21:30 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	12,648	$0.00 Strike: $64.92	$0.00	Disclosure SEC source: 0001127602-24-014818 · form4.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,648 Underlying: Common Stock · 12,648 shares Expires 2034-05-08 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document
May 08, 2024 Filed May 9, 2024 21:30 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	2,310	$0.00	$0.00	Disclosure SEC source: 0001127602-24-014818 · form4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,822 F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024. Read SEC document
February 02, 2024 Filed Feb 6, 2024 23:01 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	2,996	$0.00 Strike: $76.96	$0.00	Disclosure SEC source: 0001127602-24-003597 · form4.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,996 Underlying: Common Stock · 2,996 shares Expires 2034-02-02 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of February 2, 2024. Read SEC document
February 02, 2024 Filed Feb 6, 2024 23:01 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	512	$0.00	$0.00	Disclosure SEC source: 0001127602-24-003597 · form4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512 F1 · security: Represents 512 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of February 2, 2024. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:39 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerRestricted Stock Units · Derivative	2,044	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-070880 · ownership.xml · derivative · entry 6 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,044 shares Expires not disclosed F5 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:39 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerRestricted Stock Units · Derivative	449	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-070880 · ownership.xml · derivative · entry 5 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 449 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:39 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	3,676	Not disclosed Strike: $135.63	Not disclosed	Disclosure SEC source: 0000950170-23-070880 · ownership.xml · derivative · entry 4 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,676 shares Expires 2032-05-13 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:39 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	3,462	Not disclosed Strike: $147.50	Not disclosed	Disclosure SEC source: 0000950170-23-070880 · ownership.xml · derivative · entry 3 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,462 shares Expires 2031-05-14 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:39 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	4,460	Not disclosed Strike: $161.82	Not disclosed	Disclosure SEC source: 0000950170-23-070880 · ownership.xml · derivative · entry 2 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,460 shares Expires 2030-08-17 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:39 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerCommon Stock	4,255	$229.00	$974,395.00	Disclosure SEC source: 0000950170-23-070880 · ownership.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · shares: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · price: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). Read SEC document
August 03, 2023 Filed Aug 4, 2023 21:34 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	GrantStock option (right to buy) · Derivative	75,000	$0.00 Strike: $10.57	$0.00	Disclosure SEC source: 0001209191-23-044640 · doc4.xml · derivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires 2033-08-02 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of August 3, 2023. F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document
June 23, 2023 Filed Jun 26, 2023 20:11 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	7,747	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039689 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,941 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
May 31, 2023 Filed Jun 2, 2023 18:22 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	2,044	$0.00	$0.00	Disclosure SEC source: 0001203311-23-000062 · edgardoc.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,748 F1 · security: These securities are restricted stock units and will be settled in common stock upon vesting. F2 · shares: These restricted stock units shall vest in full on May 31, 2024. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	118,090	Not disclosed Strike: $29.87	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 18 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,090 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	132,433	Not disclosed Strike: $44.48	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 17 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,433 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	114,190	Not disclosed Strike: $65.82	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 16 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,190 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	145,000	Not disclosed Strike: $48.44	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 15 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	122,000	Not disclosed Strike: $59.60	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 14 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 122,000 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	114,515	Not disclosed Strike: $16.40	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 13 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,515 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	141,400	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 12 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 141,400 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6 · price: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. F6 · derivative.exercise_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. F6 · derivative.expiration_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	109,116	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 11 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,116 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 36,239 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	63,768	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 10 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,768 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	47,223	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 9 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,223 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	26,865	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 8 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,865 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	11,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · derivative · entry 7 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	2,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · nonDerivative · entry 6 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughter Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	2,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · nonDerivative · entry 5 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughter Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	102,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · nonDerivative · entry 4 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust 3 Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	119,650	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · nonDerivative · entry 3 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust 2 Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	119,650	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust 1 Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	576,318	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033149 · doc4.xml · nonDerivative · entry 1 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
September 27, 2022 Filed Sep 30, 2022 00:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	18,291	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0000899243-22-032261 · doc4.xml · derivative · entry 9 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,515 Underlying: Common Stock · 18,291 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of Common Stock underlying the option vested in equal quarterly installments over 16 quarters from January 17, 2017 through January 17, 2021. Read SEC document
September 27, 2022 Filed Sep 30, 2022 00:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	18,291	$16.40	$299,972.40	Disclosure SEC source: 0000899243-22-032261 · doc4.xml · nonDerivative · entry 5 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 13, 2022 Filed Sep 30, 2022 00:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GiftCommon Stock	17,650	$0.00	$0.00	Disclosure SEC source: 0000899243-22-032261 · doc4.xml · nonDerivative · entry 4 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust 2 Disclosed balance after: 119,650 Read SEC document
September 13, 2022 Filed Sep 30, 2022 00:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GiftCommon Stock	17,650	$0.00	$0.00	Disclosure SEC source: 0000899243-22-032261 · doc4.xml · nonDerivative · entry 3 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust 1 Disclosed balance after: 119,650 Read SEC document
September 13, 2022 Filed Sep 30, 2022 00:45 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GiftCommon Stock	35,300	$0.00	$0.00	Disclosure SEC source: 0000899243-22-032261 · doc4.xml · nonDerivative · entry 2 LOVE TED W · CIK 0001188919 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,027 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.